Table 3 Medications and doses of all 21 subjects enrolled in the study
Patient | Medication group | Medication name | Dose/unit | Freq |
|---|---|---|---|---|
1 | INSTI | Descovy + Isentress | 600 (2)-200-25 | QD |
2 | INSTI | Truvada and Tivicay | 200 | QD |
3 | INSTI | Triumeq | 600-50-300 | QD |
4 | INSTI | Triumeq | 600-50-300 | QD |
5 | INSTI | Genvoya | 150-150-200 | QD |
6 | INSTI | Biktarvy | 50-200-25 | QD |
7 | INSTI | Tivicay and Descovy | 50-200-25 | QD |
8 | ||||
9 | INSTI | Juluca | 50-25 | QD |
10 | NNRTI | Odefsey (Rilpivirine) | 200-25-25 | QD |
11 | INSTI | Juluca | 50-25 | QD |
12 | INSTI | Genvoya | 150-150-200 | QD |
13 | NNRTI | Odefsey | 200-25-25 | QD |
14 | NNRTI | Atripla (Efivarenz) | 600-200-300 | QD |
15 | Patient dropped out | |||
16 | NNRTI | Odefsey | 200-25-25 | QD |
17 | INSTI | Biktarvy | 50-200-25 | QD |
18 | NNRTI | Odefsey | 200-25-25 | QD |
19 | NNRTI | Epzicom + Viramune | 600-300 | QD |
20 | ||||
21 | INSTI | Descovy + Isentress | 200-25 | QD |
22 | INSTI | Descovy + Tivacay | 200-25 | QD |